论文部分内容阅读
RAS/RAF/丝裂原活化蛋白/细胞外信号调节激酶(ERK)激酶(MEK)/ERK介导的血管生成信号在肝细胞癌(HCC)的发展中发挥重要作用。索拉非尼是一种口服的RAS/RAF激酶受体和包括血管内皮生长因子受体(VEGFR)、血小板衍生生长因子受体(PDGFR)、FLT3基因、RET和c-Kit受体在内的几个酪氨酸激酶受体的抑制剂,这些受体参与了血管生成和细胞增殖。索拉非尼在体外研究、不同类型的肿瘤、临床试验、临床异种移植模型中均被证明具有抗肿瘤活性。全文对索拉非尼的作用机制、临床研发历史以及正在进行的索拉非尼联合肝动脉栓塞化疗(TACE)治疗肝细胞癌的临床试验作一综述。
RAS / RAF / mitogen-activated protein / extracellular signal-regulated kinase (MEK) / ERK-mediated angiogenic signaling plays an important role in the development of hepatocellular carcinoma (HCC). Sorafenib is an orally administered RAS / RAF kinase receptor and is involved in a variety of cytokines, including vascular endothelial growth factor receptor (VEGFR), platelet derived growth factor receptor (PDGFR), FLT3 gene, RET and c-Kit receptors Several tyrosine kinase receptor inhibitors, these receptors involved in angiogenesis and cell proliferation. Sorafenib has been shown to have anti-tumor activity in in vitro studies, various types of tumors, clinical trials, and clinical xenograft models. The full text of the mechanism of sorafenib, clinical development history and ongoing Sorafenib combined with hepatic arterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma clinical review is reviewed.